Adial Pharmaceuticals Inc
ADIL0.421USD
-0.034-7.38%
Market hours （ET）Quotes delayed by 15 min
2.80MMarket Cap
LossP/E TTM
More Details of Adial Pharmaceuticals Inc Company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
Ticker SymbolADIL
Company nameAdial Pharmaceuticals Inc
IPO dateJul 27, 2018
CEOMr. Cary J. Claiborne
Number of employees5
Security typeOrdinary Share
Fiscal year-endJul 27
Address1180 Seminole Trail
CityCHARLOTTESVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code22901
Phone14344229800
Websitehttps://www.adialpharma.com/
Ticker SymbolADIL
IPO dateJul 27, 2018
CEOMr. Cary J. Claiborne
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jun 26
Updated: Thu, Jun 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
2.83%
Armistice Capital LLC
2.13%
Geode Capital Management, L.L.C.
0.44%
Claiborne (Cary J)
0.39%
Manchester Capital Management LLC
0.30%
Other
93.91%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
2.83%
Armistice Capital LLC
2.13%
Geode Capital Management, L.L.C.
0.44%
Claiborne (Cary J)
0.39%
Manchester Capital Management LLC
0.30%
Other
93.91%
Shareholder Types
Shareholders
Proportion
Corporation
2.87%
Hedge Fund
2.14%
Investment Advisor
0.81%
Individual Investor
0.55%
Investment Advisor/Hedge Fund
0.52%
Research Firm
0.17%
Other
92.95%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
42
1.11M
7.05%
+634.10K
2025Q1
47
689.84K
5.40%
+187.97K
2024Q4
48
754.24K
11.65%
+358.52K
2024Q3
48
655.01K
10.15%
+196.50K
2024Q2
52
406.15K
9.73%
-89.94K
2024Q1
55
354.85K
11.69%
-103.82K
2023Q4
57
427.66K
35.11%
+158.29K
2023Q3
58
246.51K
21.22%
-160.46K
2023Q2
57
280.03K
24.62%
-99.13K
2023Q1
59
253.51K
23.06%
-132.71K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
446.28K
2.83%
+446.28K
--
Jun 20, 2025
Armistice Capital LLC
336.31K
2.13%
+336.31K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
68.85K
0.44%
+7.00K
+11.32%
Mar 31, 2025
Claiborne (Cary J)
60.80K
0.39%
--
--
Jun 04, 2025
Manchester Capital Management LLC
48.10K
0.3%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
47.74K
0.3%
+26.73K
+127.16%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
27.77K
0.18%
--
--
Mar 31, 2025
Virtu Americas LLC
26.41K
0.17%
+26.41K
--
Mar 31, 2025
Newman (James W. Jr.)
13.54K
0.09%
--
--
Jun 04, 2025
The Vanguard Group, Inc.
13.16K
0.08%
+3.80K
+40.60%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
Date
Type
Ratio
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
Aug 04, 2023
Merger
25<1
